Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics, Inc. (ARQT) filed a Form 144 indicating a planned disposition of 89 common shares (≈ $1,255 market value) through Merrill Lynch on or after 4 Aug 2025. The shares represent <0.0001% of the company’s 119.2 million shares outstanding and were acquired via a restricted-stock vest on 1 Aug 2024.
The same insider, Latha Vairavan, previously sold an identical block of 89 shares for $1,329 on 5 May 2025. No other sales or material considerations are disclosed. Form 144 requires the filer to state that they possess no undisclosed adverse information and to acknowledge potential penalties for misstatements.
Investment-relevance: The proposed sale is de minimis and does not alter ownership structure, liquidity, or strategic outlook. It is therefore unlikely to affect ARQT’s valuation or trading dynamics.
Director Howard G. Welgus of Arcutis Biotherapeutics (ARQT) reported a significant insider sale transaction executed on June 18, 2025. The director sold 10,139 shares of common stock at a weighted average price of $13.3715 per share, with individual transaction prices ranging from $13.2118 to $13.59.
Following the transaction, Welgus retains direct ownership of 109,414 shares of the company's common stock. The sale was conducted under a pre-established 10b5-1 trading plan initiated on March 11, 2025, which remains active until May 29, 2026.
Key transaction details:
- Transaction executed pursuant to Rule 10b5-1 trading plan
- Total transaction value approximately $135,575
- Represents a partial reduction of the director's holdings
- Transaction reported within required SEC filing deadlines